Psychiatric co-morbidity with type 1 and type 2 diabetes mellitus;Comorbidité psychiatrique et diabète de type 1 et de type 2

Eastern Mediterranean Health Journal

Volumn 17, Issue 10, 2011, Pages 777-783

  Coclami, T ^a   Cross, M ^a  

^a CITY UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BIPOLAR II DISORDER; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HOSPITAL ADMISSION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MENTAL PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; OUTCOME ASSESSMENT; PATIENT EDUCATION; PREVALENCE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 80054872047     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2011.17.10.777     Document Type: Article

References (28)

1. Blanz BJ et al. IDDM is a risk factor for adolescent psychiatric disorders. Diabetes Care, 1993, 16:1579-1587.
2. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. American Journal of Psychiatry, 1999, 156:1417-1420.
3. Mukherjee S et al. Diabetes mellitus in schizophrenic patients Comprehensive Psychiatry, 1996, 37:68-73.
4. Regenold WT et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. Journal of Affective Disorders, 2002, 70:19-26.
5. Ruzickova M et al. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Canadian Journal of Psychiatry, 2003, 48:458-461.
6. Shaw E, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice, 2010, 87:4-14
7. Rubin RR et al. Recognising and treating depression in patients with diabetes. Current Diabetes Reports, 2004, 4:119-125.
8. Lustman PJ, Anderson R. Depression in adults with diabetes. Psychiatric Times, 2002, 19:45-48
9. Lustman PJ et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosomatic Medicine, 1997, 59:241-250
10. Maudsley H. The physiology and pathology of the mind. London, Macmillan, 1867.
11. Lindenmayer J-P et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry, 2003, 160:290-296.
12. Sernyak MJ et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry, 2002, 159:561-566.
13. Dinan T. Schizophrenia and diabetes 2003: an expert consensus meeting: Introduction. British Journal of Psychiatry, 2004, 184(Suppl. 47):S53-S54.
14. Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC, American Psychiatric Association, 1994.
15. Craig TJ et al. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? American Journal of Psychiatry, 2000, 157:60-66.
16. Lee AS, Murray RM. The long-term outcome of Maudsley depressives. British Journal of Psychiatry, 1988, 153:741-751.
17. Carpenter WT et al. Decisional capacity for informed consent in schizophrenia research. Archives of General Psychiatry, 2000, 57:533-538.
18. Stroup S et al. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research, 2005, 80:1-8.
19. Goodnick P. Treatment of depression in patients with diabetesmellitus. Journal of Clinical Psychiatry, 1995, 56(4):128-36.
20. Buse JB et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology, 2003, 56:164-170.
21. Koro CE et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ (Clinical Research Ed.), 2002, 325:243-248.
22. Lambert B et al. Assessing the risk of antipsychotic-induced type II diabetes among schizophrenics: a matched case control study. European Neuropsychopharmacology, 2002, 12(Suppl. 3):S307-S308.
23. Bushe C, Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. British Journal of Psychiatry, 2004, 184 (Suppl. 47):S87-S93.
24. Evans K, Sullivan JM. Dual diagnosis: counseling the mentally ill substance abuser. New York, Guilford Press, 1990.
25. Global burden of disease. Geneva, World Health Organization, 1990.
26. Mental health care. The Institute of Psychiatry, South London and Maudsley NHS Foundation Trust, Rethink, The Wellcome Trust [webpage]. Discrimination and stigma (http://www.mentalhealthcare.org.uk/discrimination_and_stigma, accessed 6 September 2011).
27. Waddington JL et al. Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics? Journal of Psychiatric Research, 1998, 32:179-189.
28. Jackson C, Birchwood M. Early intervention in psychosis: opportunities for secondary prevention. British Journal of Clinical Psychology, 1996, 35:487-502.